Back to Search Start Over

The Highly Potent AhR Agonist Picoberin Modulates Hh-Dependent Osteoblast Differentiation.

Authors :
Flegel J
Shaaban S
Jia ZJ
Schulte B
Lian Y
Krzyzanowski A
Metz M
Schneidewind T
Wesseler F
Flegel A
Reich A
Brause A
Xue G
Zhang M
Dötsch L
Stender ID
Hoffmann JE
Scheel R
Janning P
Rastinejad F
Schade D
Strohmann C
Antonchick AP
Sievers S
Moura-Alves P
Ziegler S
Waldmann H
Source :
Journal of medicinal chemistry [J Med Chem] 2022 Dec 22; Vol. 65 (24), pp. 16268-16289. Date of Electronic Publication: 2022 Dec 02.
Publication Year :
2022

Abstract

Identification and analysis of small molecule bioactivity in target-agnostic cellular assays and monitoring changes in phenotype followed by identification of the biological target are a powerful approach for the identification of novel bioactive chemical matter in particular when the monitored phenotype is disease-related and physiologically relevant. Profiling methods that enable the unbiased analysis of compound-perturbed states can suggest mechanisms of action or even targets for bioactive small molecules and may yield novel insights into biology. Here we report the enantioselective synthesis of natural-product-inspired 8-oxotetrahydroprotoberberines and the identification of Picoberin, a low picomolar inhibitor of Hedgehog (Hh)-induced osteoblast differentiation. Global transcriptome and proteome profiling revealed the aryl hydrocarbon receptor (AhR) as the molecular target of this compound and identified a cross talk between Hh and AhR signaling during osteoblast differentiation.

Details

Language :
English
ISSN :
1520-4804
Volume :
65
Issue :
24
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
36459434
Full Text :
https://doi.org/10.1021/acs.jmedchem.2c00956